![](/img/cover-not-exists.png)
E13Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months:
Sobrero, A., Grothey, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouche, O., Mineur, L., Barone, C., Adenis, A., Tabernero, J., Yoshino, T., Lenz, H., Goldberg, R.M., Xu, L., Wagner, A., VanVolume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv340.13
Date:
October, 2015
File:
PDF, 43 KB
english, 2015